miRNA联合治疗对肺癌细胞周期和血管生成调控的分析  

Analysis of miRNA Combination Therapy on Lung Cancer Cell Cycle and Angiogenesis

作　　者：方梅 陈园 FANG Mei;CHEN Yuan(The Fifth People's Hospital of Shanghai,Fudan University,Shang Hai 200240,China)

机构地区：[1]上海市第五人民医院,上海200240

出　　处：《药物生物技术》2020年第3期221-226,共6页Pharmaceutical Biotechnology

摘　　要：肺癌是全球范围内与癌症相关的死亡的主要原因。与其他癌细胞相似,肺癌细胞的最主要的特点是细胞本身无法控制其增殖和分裂过程。作为目前最为重要的转录后基因重要调节剂——miRNA治疗剂,正在被越来越多地研究用于癌症治疗。为研究分析miRNA对肺癌细胞周期和血管生成的调控作用机制。在该研究中,作者利用了两个miRNA,即miR-143和miR-506,来调节细胞周期进程。转染A549非小细胞肺癌(NSCLC)细胞,分析基因表达变化,并最终分析治疗引起的凋亡活性。这次研究的结果发现,细胞周期蛋白依赖性激酶(CDK)(指的是CDK1,CDK4和CDK6)的表达呈现下调趋势,并在G1/S和G2/M相变处停止细胞周期。作者的实验结果还表明该疗法具有潜在的抗血管生成活性,这使该方法在抗癌方面具有较大的应用前景。lung cancer is the leading cause of cancer-related deaths worldwide.Similar to other cancer cells,the basic characteristics of lung cancer cells are uncontrolled proliferation and cell division.MiRNA therapeutics have become important post transcriptional gene regulators,and are being used in cancer therapy more and more.To study the regulatory mechanism of miRNA on cell cycle and angiogenesis of lung cancer.in this study,we used two miRNAs,miR-143 and mir-506,to regulate cell cycle.A549 non-small cell lung cancer(NSCLC)cells were transfected to analyze the changes of gene expression and the apoptotic activity.The author’s results detected the downregulation of cyclin dependent kinase(CDK1,CDK4 and Cdk6),and stopped cell cycle at G1/s and G2/M phase transitions.The author’s results show that the therapy has potential anti angiogenic activity,which makes the method have great application prospects in anti-cancer.

关 键 词：MIR-143 miR-506 细胞周期蛋白依赖性激酶 肺癌细胞周期 

分 类 号：R734.2[医药卫生—肿瘤] R730.50[医药卫生—临床医学]